Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30771219 | 0.85 | LTA4H (0.54) | NPC1RAB9ASMN1; SMN2ALDH1A1ALOX5 | |
| SCHEMBL10848249 | 0.84 | TSHR (0.49) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL6803017 | 0.82 | ALOX5 (0.59) | NPC1RAB9AALOX5FFAR1MAOB | |
| SCHEMBL256951 | 0.81 | ALDH1A1 (0.43) | ALDH1A1ALOX5FFAR1 | |
| SCHEMBL6629953 | 0.81 | LMNA (0.61) | SMN1; SMN2ALDH1A1ALOX5FFAR1MAOB | |
| SCHEMBL14221791 | 0.81 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2ALDH1A1ALOX5 | |
| SCHEMBL15042181 | 0.77 | ALDH1A1 (0.40) | NPC1RAB9ASMN1; SMN2ALDH1A1ALOX5 | |
| SCHEMBL9149235 | 0.76 | CNR2 (0.57) | NPC1RAB9ASMN1; SMN2ALDH1A1ALOX5 | |
| SCHEMBL956766 | 0.74 | MAOB (0.60) | RAB9ASMN1; SMN2ALOX5FFAR1MAOB | |
| SCHEMBL17465915 | 0.73 | MAOB (0.64) | RAB9ASMN1; SMN2ALOX5FFAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2074127-A1 | PYRAZOLO [1, 5-A]PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008037459-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | NPC1 3655/4885RAB9A 2814/4885SMN1; SMN2 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.